

1 **Post lockdown COVID-19 seroprevalence and circulation at the time of**
2 **delivery, France**

3 **Running title**

4 COVID-19 seroprevalence & childbirth

5

6 Jérémie Mattern¹ (MD), Christelle Vauloup-Fellous² (PD, PhD), Hoda Zakaria¹ (MD),
7 Alexandra Benachi¹ (MD, PhD), Julie Carrara¹ (MD), Alexandra Letourneau¹ (MD), Nadège
8 Bourgeois-Nicolaos³ (PD, PhD), Daniele De Luca⁴ (MD, PhD), Florence Doucet-Populaire³
9 (MD, PhD), Alexandre J. Vivanti^{1,*} (MD, PhD)

10

11 1. Division of Obstetrics and Gynecology, Antoine Béclère Hospital, Paris Saclay

12 University, AP-HP, Clamart, France

13 2. Division of Virology, Paul Brousse Hospital, Paris Saclay University, AP-HP, INSERM

14 U1193 Villejuif, France

15 3. Division of Microbiology, Antoine Béclère Hospital, Paris Saclay University, AP-HP,

16 Clamart, France

17 4. Division of Pediatrics and Neonatal Critical Care, Antoine Béclère Hospital, Paris Saclay

18 University, AP-HP, Clamart, France

19

20 * Corresponding author

21 Alexandre J. Vivanti, Service de Gynécologie-Obstétrique

22 Ho

pital A. Béclère, GHU Paris Saclay, APHP.

23 157 rue de la Porte de Trivaux

24 92140 Clamart, France

25 Tel: +33 (0)145374441 - Fax: +33 (0)145374366 - Email: alexandre.vivanti@aphp.fr

26

27 **Abstract**

28

29 **Background**

30

31 To fight the COVID-19 pandemic, lockdown has been decreed in many countries worldwide.
32 The impact of pregnancy as a severity risk factor is still debated, but strict lockdown measures
33 have been recommended for pregnant women.

34

35 **Objectives**

36

37 To evaluate the impact of the COVID-19 pandemic and lockdown on the seroprevalence and
38 circulation of SARS-CoV-2 in a maternity ward in an area that has been significantly affected
39 by the virus.

40

41 **Study design**

42

43 Prospective study at the Antoine Bécélère Hospital maternity ward (Paris area, France) from
44 May 4 (one week before the end of lockdown) to May 31, 2020 (three weeks after the end of
45 lockdown). All patients admitted to the delivery room during this period were offered a
46 SARS-CoV-2 serology test as well concomitant SARS-CoV-2 RT-PCR on a nasopharyngeal
47 sample.

48

49 **Results**

50

51 A total of 249 women were included. Seroprevalence of SARS-CoV-2 was 8%. The RT-PCR
52 positive rate was 0.5%. 47.4% of the SARS-CoV-2-IgG-positive pregnant women never
53 experienced any symptoms. A history of symptoms during the epidemic, such as fever,
54 myalgia and anosmia, was suggestive of previous infection.

55

56 **Conclusions**

57

58 Three weeks after the end of lockdown, SARS-CoV-2 infections were scarce in our region. A
59 high proportion of SARS-CoV-2-IgG-negative pregnant women must be taken into
60 consideration in the event of a resurgence of the pandemic in order to adapt public health
61 measures to reduce exposure to the virus, such as social distancing and teleworking for this
62 specific population.

63

64

65

66

67 **Introduction**

68

69 The coronavirus disease 2019 (COVID-19) pandemic hit France at the end of
70 February 2020. To date (June 15, 2020), more than 7,000,000 cases and 400,000 deaths have
71 occurred worldwide.[1] France, and more particularly the Paris area, was one of the regions of
72 the world most affected by the pandemic. In order to slow down progression of the pandemic,
73 lockdown has been decreed in many countries worldwide. French lockdown started on March
74 17, 2020, and ended on May 11, 2020.

75

76 Pregnancy as a severity risk factor of severe acute respiratory syndrome coronavirus 2
77 (SARS-CoV-2) infection is still debated, even though the third trimester seems to be a
78 consensual risk factor[2–7]. The main goal of this study was to evaluate the impact of the first
79 wave of the COVID-19 pandemic in our region and the effect of lockdown on seroprevalence
80 in our maternity ward, which has been significantly affected by the virus (more than 40
81 confirmed infections among pregnant women between March 12 and April 20).

82 **Materials and Methods**

83

84 We conducted a prospective study at the Antoine Bécclère Hospital maternity ward
85 (Paris area, France) from May 4 (one week before the end of lockdown) to May 31, 2020
86 (three weeks after the end of lockdown). All patients admitted to the delivery room during
87 this period were offered a SARS-CoV-2 serology test as well as SARS-CoV-2 RT-PCR on a
88 nasopharyngeal sample. A questionnaire was distributed to all included women, who were
89 asked about symptoms (fever, cough, dyspnea, myalgia, anosmia, diarrhea and rash) affecting
90 them and/or close relatives (household residents) from January 1 to their delivery, and if there
91 were symptoms they were asked for the date of onset. Patients were also asked whether they
92 strictly adhered to the rules of lockdown and social distancing.

93

94 Serology testing

95 Serum samples were run on the Abbott Architect instrument using the Abbott SARS-
96 CoV-2 IgG assay (Abbott, Sligo, Ireland) following the manufacturer's instructions. The
97 assay is a chemiluminescent microparticle immunoassay for detection in human serum or
98 plasma of IgG against the SARS-CoV-2 nucleocapsid protein. Based on our local evaluation
99 of 500 serum samples (data not published), the result was considered negative if the IgG
100 index value was < 0.8 , equivocal if the IgG index was between 0.8 and 1.39, and positive if
101 the IgG index value was ≥ 1.40 (0.40 is the Abbott determined positivity cut-off).

102

103 Molecular testing

104 Nasopharyngeal swabs were collected from all the patients. Samples were tested by
105 using the GeneFinder™ COVID-19 Plus RealAmp Kit on the ELITE InGenius® Platform, or

106 the Xpert Xpress SARS-CoV-2 assay (Cepheid), or the GenMark ePlex SARS-CoV-2 assay,
107 depending on the time of day.

108 The GeneFinder assay is a molecular in vitro test utilizing one-step reverse transcription real-
109 time PCR to detect the RNA-dependent RNA polymerase, the envelope gene (E) and the
110 nucleocapsid gene (N), as described in international guidelines (Corman *et al.*[8])

111 The Xpert Xpress SARS-CoV-2 assay (Cepheid) and the GenMark ePlex SARS-CoV-
112 2 assay are sample-to-answer molecular diagnostic platforms. The former is based on the
113 detection of 2 gene targets, N2 and E, according to an algorithm in parallel with the sample
114 process control, and the latter is based on the detection of the N gene of SARS-CoV-2.

115

116 All data (clinical, laboratory, from both mothers and newborns) were prospectively
117 collected from medical records.

118

119 All statistical analyses were performed using R software (Version 3.5.1, R Core Team
120 [2018] <https://www.R-project.org/>). Continuous variables are expressed as medians with
121 interquartile range (IQR). Categorical variables are expressed as numbers with percentages. A
122 two-tailed Mann-Whitney U test was used for statistical analysis of continuous variables.

123 Fisher's exact test was used for statistical analysis of categorical variables. Statistical

124 significance was considered with a $p < 0.05$.

125

126 This study was approved by the institutional review board of the French College of
127 Obstetricians and Gynecologists (2020-OBST-0408) and was performed in accordance with
128 the Declaration of Helsinki. All patients gave written consent. All data were de-identified to
129 ensure patient privacy and confidentiality.

130

131

132 **Results**

133

134 During the study period, SARS-CoV-2 serology testing was offered to all 272 patients
135 admitted to the delivery room (figure 1). A total of 249 (91.5%) serology results were
136 available (22 women did not give consent and one missing result). Seroprevalence was 8%
137 (n=20/249). The main characteristics of the women and of their pregnancies and newborns are
138 shown in Table 1. All patients were asymptomatic on admission to the delivery room. There
139 were no significant differences between the groups of SARS-CoV-2-IgG-positive and SARS-
140 CoV-2-IgG-negative women. Among women admitted for delivery, 190 had a SARS-CoV-2
141 RT-PCR test during the study period (59 women declined testing and one missing result).
142 Exhaustivity was therefore of 69.9% (190/272). Only one (0.5%) test was positive and this
143 patient remained asymptomatic during delivery and early post-partum. This positive test was
144 performed on May 25, 2020, using the Xpert Xpress assay, with detection of the N2 gene at a
145 CT value of 41.4, which corresponds to a very low viral load, which may be related to an old
146 infection. The serology was positive. The patient and her spouse reported symptoms such as
147 headache, asthenia and anosmia as of March 10, 2020. Her newborn tested negative (negative
148 SARS-CoV-2 RT-PCR performed on nasopharyngeal swabs at birth and at three days of life).

149

150

151 **Figure 1: Flow chart of the study – Universal serology screening for SARS-CoV-2**
152 **among a cohort of women admitted for delivery**

153

| Table 1: Maternal, obstetric and neonatal characteristics according to SARS-CoV-2 serological status for women admitted for delivery | | | |
|---|-------------------------------|------------------------------|-------------|
| | IgG-negative n=229 | IgG-positive n=20 | p |
| Age, years, median [IQR] | 33 [29-36] | 31 [30.5-37] | 0.88 |

| | | | |
|--|------------------|------------------|------|
| Nullipara, n (%) | 106 (46.3) | 12 (60) | 0.25 |
| BMI, kg/m ² , median [IQR] | 23 [21-27] | 25,5 [23-28.2] | 0.07 |
| History of preexisting: | | | |
| - Diabetes mellitus, n (%) | 2 (0.9) | 0 (0) | 1 |
| - Chronic hypertension, n (%) | 6 (2.6) | 0 (0) | 1 |
| - Tobacco use, n (%) | 44 (19.2) | 2 (10.6) | 0.54 |
| - Asthma, n (%) | 13 (5.7) | 0 (0) | 0.6 |
| | | | |
| Gestational age at delivery, week median [IQR] | 39.6 [38.2-40.7] | 39.7 [38.2-40.3] | 0.50 |
| Delivery before 37 WG, n (%) | 26 (11.4) | 4 (21.1) | 0.26 |
| Birthweight, g median [IQR] | 3241 [2829-3585] | 3213 [2853-3471] | 0.62 |
| Infected neonates, n (%) | 0 (0) | 0 (0) | |

154

155

156 Analysis of the available questionnaires (n=220/249; 88.3%) showed that 47.4%
 157 (9/19) of the SARS-CoV-2-IgG-positive women reported being asymptomatic throughout the
 158 first wave of the pandemic. SARS-CoV-2-IgG-positive women reported more symptoms
 159 compared to SARS-CoV-2-IgG-negative women (Table 2), such as fever (n=3 (15.8%) versus
 160 n=3 (1.5%); OR=12.9 (95% CI 1.49-97.52) ; p=0.009), myalgia (n=7 (36.8%) versus n=14
 161 (7%); OR=8.39 (95% CI 2.38-25.46); p<0.001) and anosmia (n=6 (31.6%) versus n=3
 162 (1.5%); OR=29.2 (95% CI 5.52-201); p<0.001). There was no difference regarding the
 163 symptoms of cough, dyspnea, diarrhea and rash. All women except one reported they had
 164 strictly respected lockdown rules.

165

166

| | IgG-negative n=201 | IgG-positive n=19 | OR (95% CI) | p |
|----------------|-----------------------|----------------------|----------------------|-------|
| Fever, n (%) | 3 (1.5) | 3 (15.8) | OR=12.9 (1.49-97.52) | 0.009 |
| Cough, n (%) | 13 (6.5) | 2 (10.5) | OR=1.69 (0.17-8.52) | 0.62 |
| Dyspnea, n (%) | 12 (6) | 1 (5.3) | OR=0.87 (0.02-6.6) | 1 |

| | | | | |
|-----------------|-----------|----------|----------------------|--------|
| Myalgia, n (%) | 14 (7) | 7 (36.8) | OR=8.39 (2.19-25.46) | <0.001 |
| Anosmia, n (%) | 3 (1.5) | 6 (31.6) | OR=29,2 (5.52-201) | <0.001 |
| Diarrhea, n (%) | 21 (10.4) | 1 (5.3) | OR=0.47 (0.01-3.34) | 0,7 |
| Rash, n (%) | 5 (2.5) | 1 (5.3) | OR=2.16 (0.04-20.9) | 0.42 |

167

168 **Discussion**

169

170 SARS-CoV-2 screening (serology and RT-PCR on nasopharyngeal secretions) of all
171 women at delivery showed that: 1- the seroprevalence of SARS-CoV-2 infection was 8% and
172 most of the pregnant women remained uninfected; 2- half of the SARS-CoV-2-IgG-positive
173 pregnant women were completely asymptomatic; 3- the virus was no longer circulating up to
174 three weeks after the end of the lockdown.

175

176 In our maternity ward, implementation and generalized respect of lockdown rules and
177 social distancing allowed for a drastic reduction in the number of confirmed cases. Pregnant
178 women reported full lockdown compliance from March 17, 2020 until delivery. Despite the
179 end of lockdown and the resumption of activity for members of the family circle, the rate of
180 positive results by RT-PCR remained very low. In addition, reported symptoms such as fever,
181 myalgia and anosmia were linked with previous infection with the SARS-CoV-2 virus.

182

183 The seroprevalence of our cohort was similar to that recently observed in the general
184 population[9,10]. To date, it has not been assessed whether SARS-CoV-IgG, detected with
185 currently available ELISA assays, are neutralizing antibodies and consequently confer
186 protection. However, it is of major importance to have an estimation of the rate of pregnant
187 women who have not already been infected, in order to implement adapted measures in the
188 event of a second outbreak, such as social distancing and teleworking at least for this specific
189 population [11,12].

190

191 One could argue that the study period would need to be longer in order to fully
192 estimate the effect of the end of the lockdown and the risk of a resumption of the pandemic

193 (so-called second wave). However, we believe that our study provides an important snapshot

194 at a given point in time of the exposure to COVID-19 in an at-risk population in a region

195 highly exposed to the virus.

196

197 **Acknowledgments**

198 We would like to thank David Marsh for language editing.

199

200 **Conflict of interests**

201 None

202

203 **Funding**

204 None

205

206

207

208

209

210

211

212

213

214

215 **References**

216

- 217 1. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200609-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200609-covid-19-sitrep-141.pdf?sfvrsn=72fa1b16_2)
218 [covid-19-sitrep-141.pdf?sfvrsn=72fa1b16_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200609-covid-19-sitrep-141.pdf?sfvrsn=72fa1b16_2).
- 219 2. Yin M, Zhang L, Deng G, Han C, Shen M, Sun H, et al. Severe Acute Respiratory
220 Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Pregnancy In China: A
221 Retrospective Cohort Study. medRxiv. 2020; 2020.04.07.20053744.
222 doi:10.1101/2020.04.07.20053744
- 223 3. Wei L, Jing W, Wenbin L, Zhaoxian Z, Siying L, Zhihui R. Clinical characteristics of 19
224 neonates born to mothers with COVID-19. *Frontiers of Medicine*. doi:10.1007/s11684-
225 020-0772-y
- 226 4. Liu D, Li L, Wu X, Zheng D, Wang J, Yang L, et al. Pregnancy and Perinatal Outcomes
227 of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis.
228 *American Journal of Roentgenology*. 2020; 1–6. doi:10.2214/AJR.20.23072
- 229 5. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE, et
230 al. Maternal Death Due to COVID-19 Disease. *Am J Obstet Gynecol*. 2020.
231 doi:10.1016/j.ajog.2020.04.030
- 232 6. Vivanti AJ, Mattern J, Vauloup-Fellous C, Jani J, Rigonnot L, El Hachem L, et al.
233 Retrospective description of 100 pregnant women with SARS-CoV-2 infection, France.
234 *Emerg Infect Dis*. 2020.
- 235 7. Sentilhes L, De Marcillac F, Jouffrieau C, Kuhn P, Thuet V, Hansmann Y, et al.
236 COVID-19 in pregnancy was associated with maternal morbidity and preterm birth. *Am*
237 *J Obstet Gynecol*. 2020. doi:10.1016/j.ajog.2020.06.022
- 238 8. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of
239 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25.
240 doi:10.2807/1560-7917.ES.2020.25.3.2000045
- 241 9. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al.
242 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland
243 (SEROCoV-POP): a population-based study. *The Lancet*. 2020; S0140673620313040.
244 doi:10.1016/S0140-6736(20)31304-0
- 245 10. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of
246 SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California,
247 on April 10–11, 2020. *JAMA*. 2020;323: 2425–2427. doi:10.1001/jama.2020.8279
- 248 11. CDC. COVID-19 Serology Surveillance Strategy. In: Centers for Disease Control and
249 Prevention [Internet]. 11 Feb 2020 [cited 17 Jun 2020]. Available:
250 [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology-surveillance/index.html)
251 [surveillance/index.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology-surveillance/index.html)
- 252 12. Vivanti AJ, Deruelle P, Picone O, Guillaume S, Roze J-C, Mulin B, et al. Follow-up for
253 pregnant women during the COVID-19 pandemic: French national authority for health

254 recommendations. Journal of Gynecology Obstetrics and Human Reproduction. 2020;
255 101804. doi:10.1016/j.jogoh.2020.101804

256